Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
European Journal of Cancer2011Vol. 47(15), pp. 2273–2281
Citations Over TimeTop 10% of 2011 papers
Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, Jana Barinoff, Christoph Mundhenke, Tanja Čufer, E. Maartense, Felix E. de Jongh, Klaus Baumann, Joachim Bischoff, Nadia Harbeck, Hans‐Joachim Lück, Nicolaì Maass, Christoph Zielinski, Michael Andersson, Robert C. Stein, Valentina Nekljudova, Sibylle Loibl
Related Papers
- → Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer(2006)3,443 cited
- → Lapatinib: A competitor or companion to trastuzumab?(2009)8 cited
- → Nearly Complete Response of Brain Metastases from HER2 Overexpressing Breast Cancer with Lapatinib and Capecitabine after Whole Brain Irradiation(2013)4 cited
- → Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient(2013)5 cited
- → Unusual long-lasting cutaneous complete response to lapatinib and capecitabine in a heavily pretreated HER2-positive plurimetastatic breast cancer patient.(2013)3 cited